Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017

First report of data evaluating investigational selective IDO1 inhibitor alone and in combination with Opdivo Initial presentation of overall survival data from Phase 3 CheckMate -067 assessing Opdivo monotherapy or in combination with Yervoy versus Yervoy alone in patients with…

Read More
  • 1
  • 2